{"id":23320,"date":"2023-06-05T20:14:07","date_gmt":"2023-06-05T14:44:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=23320"},"modified":"2023-06-05T20:14:09","modified_gmt":"2023-06-05T14:44:09","slug":"lexicon-inpefa-for-heart-failure-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment","title":{"rendered":"LEXICON\u2019s INPEFA: Entry of Another Drug for Heart Failure Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a10988a5bcdc\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a10988a5bcdc\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment\/#Current_Heart_Failure_Treatment_Space\" >Current Heart Failure Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment\/#LEXICONs_INPEFA_Potential_Competitor_to_AstraZenecas_Farxiga_and_Lillys_Jardiance\" >LEXICON\u2019s INPEFA: Potential Competitor to AstraZeneca\u2019s Farxiga and Lilly\u2019s Jardiance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment\/#Promising_Future_of_Heart_Failure_Treatment_Market\" >Promising Future of Heart Failure Treatment Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Heart failure is a global pandemic that affects at least <strong>26 million<\/strong> people globally and is becoming more common. Heart failure health expenditures are substantial and will rise considerably as the population ages. Despite significant advancements in medicines and prevention, mortality and morbidity remain high, and quality of life remains low. The reported prevalence, incidence, mortality, and morbidity rates vary geographically, based on the many etiologies and clinical features identified in heart failure patients.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>As per the DelveInsight estimates, the <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-chf-epidemiology-forecast\"><em>heart failure diagnosed prevalence<\/em><\/a><em> was&nbsp; <\/em><strong><em>7 million<\/em><\/strong><em> in the US in 2022. As per the estimates, around 4 million males and approximately <\/em><strong><em>3 million<\/em><\/strong><em> females were suffering from heart failure in the US in 2022, which is expected to increase during the forecast period (2023\u20132032).<\/em>&nbsp;&nbsp;&nbsp;<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-heart-failure-treatment-space\"><span class=\"ez-toc-section\" id=\"Current_Heart_Failure_Treatment_Space\"><\/span><strong>Current Heart Failure Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/heart-failure-market\">heart failure treatment market<\/a> is highly competitive, with pharma companies competing to produce best-in-class treatments to reduce the burden of heart failure. <strong>Novartis\u2019 Entresto (sacubitril\/valsartan)<\/strong> is a first-in-class angiotensin-receptor\/neprilysin inhibitor that has been licensed and sold for the treatment of chronic heart failure with decreased ejection fraction (HFrEF). This drug was approved in the United States in July 2015 for chronic heart failure with a decreased ejection fraction; in Europe, it was approved in November 2015 and again in October 2019 for pediatric patients with heart failure. Novartis announced in February 2021 that the US FDA had approved the following extended indication for <strong>Entresto (sacubitril\/valsartan)<\/strong> to lower the risk of cardiovascular death and hospitalization for heart failure in adult patients with CHF.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/congestive-heart-failure-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-1024x194.png\" alt=\"Heart Failure Infographics\" class=\"wp-image-23325\" width=\"768\" height=\"146\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101549\/Heart-Failure-Infographics.png 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Jardiance<\/strong>, manufactured by <strong>Boehringer Ingelheim and Eli Lilly,<\/strong> is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is indicated as an adjunct to diet and exercise to improve glycemic control in an adult\u2019s genital or perineal area, along with fever or malaise, to reduce the risk of cardiovascular death in <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">adults with type 2 diabetes mellitus<\/a> and established cardiovascular disease, and to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults. The European Commission and the FDA authorized Jardiance for the treatment of symptomatic chronic HFrEF in June and August 2021, respectively. Jardiance gained regulatory approval from Japan\u2019s MHLW in November 2021 for treating chronic heart failure in patients receiving conventional chronic heart failure medication.<\/p>\n\n\n\n<p><strong>Verquvo <\/strong>is a soluble guanylate cyclase (sGC) stimulator developed by <strong>Bayer and Merck <\/strong>that is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a heart failure hospitalization or the need for outpatient IV diuretics in adults with symptomatic chronic HF and an ejection fraction less than 45%. It is approved for heart failure in the United States, the European Union, and Japan. Merck began a Phase III pivotal trial of Verquvo in <a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-chf-epidemiology-forecast\">patients with chronic heart failure<\/a> with a decreased ejection fraction of 40% or less and no recent worsening heart failure event in 2021.<\/p>\n\n\n\n<p><strong>Farxiga <\/strong>is an <strong>AstraZeneca<\/strong> sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated in adults as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular It is approved for the <a href=\"https:\/\/www.delveinsight.com\/blog\/heart-failure-market\">treatment of heart failure<\/a> in the United States, the European Union, and Japan.<\/p>\n\n\n\n<p><strong>SAMTASU\/OPC-61815 <\/strong>is a water-soluble prodrug of oral tolvaptan (tolvaptan sodium phosphate) that is appropriate for IV delivery. Tolvaptan is a novel chemical developed by <strong>Otsuka <\/strong>that is an orally accessible antagonist of the vasopressin V2 receptor. It inhibits water reabsorption at the renal collecting duct, resulting in increased water diuresis without electrolyte depletion. The PMDA granted regulatory approval to SAMTASU 8 mg and 16 mg IV infusion in March 2022 to treat fluid retention in heart failure patients who have not reacted adequately to other diuretics, such as loop diuretics. On May 30, 2022, the product was launched in Japan.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101619\/Heart-Failure-Key-Insights-1024x614.png\" alt=\"Heart Failure Key Insights\" class=\"wp-image-23326\" width=\"512\" height=\"307\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101619\/Heart-Failure-Key-Insights-1024x614.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101619\/Heart-Failure-Key-Insights-300x180.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101619\/Heart-Failure-Key-Insights-150x90.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101619\/Heart-Failure-Key-Insights-768x461.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101619\/Heart-Failure-Key-Insights.png 1170w\" sizes=\"(max-width: 512px) 100vw, 512px\" \/><\/figure>\n\n\n\n<p><strong>FUROSCIX (furosemide injection)<\/strong> is an investigational, patented furosemide solution with a neutral pH that is designed for SC infusion via a wearable, pre-programmed on-body infusor for outpatient self-administration. It is a new furosemide formulation packed in a prefilled Crystal Zenith cartridge. FUROSCIX is the first and only FDA-approved SC loop diuretic that can be administered at home using the FUROSCIX Infusor.<\/p>\n\n\n\n<p>In January 2023, <strong>scPharmaceuticals<\/strong> announced the commercial availability of FUROSCIX on February 20, 2023, with reimbursed access to the drug for all Medicare Part D and Medicaid beneficiaries on Day 1 and that approximately 60% of all heart failure patients would have fixed tier co-pays (USD 100) at launch, with the company working hard to expand this to greater than 75% fixed tier co-pays.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"LEXICONs_INPEFA_Potential_Competitor_to_AstraZenecas_Farxiga_and_Lillys_Jardiance\"><\/span><strong>LEXICON\u2019s INPEFA: Potential Competitor to AstraZeneca\u2019s Farxiga and Lilly\u2019s Jardiance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Lexicon Pharmaceuticals, Inc. <\/strong>earned a major victory before the end of May when the FDA accepted the company\u2019s application to market <strong>sotagliflozin (brand name: Inpefa)<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-market\">heart failure treatment<\/a>. On the plus side, the FDA awarded the drug about as excellent a label as could possibly be expected. Inpefa\u2019s clinical efficacy and safety outperform proven heart failure drugs such as <strong>AstraZeneca PLC\u2019s Farxiga, Eli Lilly &amp; Company\/Boehringer Ingelheim\u2019s Jardiance, and Johnson &amp; Johnson\u2019s Invokana<\/strong>. On the negative side, there is still a lot of expensive work to be done if Lexicon is to win enough market share to make the drug genuinely profitable.<\/p>\n\n\n\n<p>The approval is based on the results of two randomized, double-blind, placebo-controlled <strong>Phase III<\/strong> cardiovascular outcomes studies of INPEFA in patients with or at risk of heart failure. <strong>SOLOIST-WHF (Worsening Heart Failure) and SCORED<\/strong> enrolled about <strong>12,000<\/strong> patients together. In individuals who had previously been hospitalized for worsening heart failure, INPEFA dramatically reduced the risk of the composite of hospitalizations for heart failure, urgent visits for heart failure, and cardiovascular mortality by <strong>33%<\/strong> compared to placebo.<\/p>\n\n\n\n<p>INPEFA is a sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1) inhibitor. The American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) recommended SGLT inhibitors as <a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-market\">first-line treatment for heart failure<\/a> in their joint 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure. An expert consensus statement issued by the American College of Cardiology (ACC) in April 2023 emphasized the value of SGLT inhibitors as part of Guideline-Directed Medical Therapy (GDMT) in patients with heart failure with preserved ejection fraction (HFpEF). The ACC expert consensus statement recommends that SGLT2 inhibitors be started in all persons with HFpEF who are stable during hospitalization and have no patient population contraindications.&nbsp;<\/p>\n\n\n\n<p>Lexicon anticipates that INPEFA will be accessible by the end of June 2023. The company intends to keep the wholesale acquisition cost of the pharmaceutical comparable to that of existing branded heart failure treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Promising_Future_of_Heart_Failure_Treatment_Market\"><\/span><strong>Promising Future of Heart Failure Treatment Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The dynamics of the heart failure treatment market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world. The drug candidates by key players, such as, <strong>Omecamtiv mecarbil (Cytokinetics), AZD4831 (AstraZeneca), Rexlemestrocel-L (Revascor) (Mesoblast), Finerenone (Kerendia) (Bayer), CXL 1427 (BMS)<\/strong>, and others that are under late- and mid-phase of clinical development have the potential to create a significant positive shift in <a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-market\">congestive heart failure market size<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05103127\/Emerging-Therapies-for-Heart-Failure.png\" alt=\"Emerging Therapies for Heart Failure\" class=\"wp-image-23347\" width=\"667\" height=\"305\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05103127\/Emerging-Therapies-for-Heart-Failure.png 889w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05103127\/Emerging-Therapies-for-Heart-Failure-300x137.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05103127\/Emerging-Therapies-for-Heart-Failure-150x69.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05103127\/Emerging-Therapies-for-Heart-Failure-768x351.png 768w\" sizes=\"(max-width: 667px) 100vw, 667px\" \/><\/figure>\n\n\n\n<p>Many clinical trials addressing the effects of drugs on HFpEF are underway, providing possible medical evidence for the future treatment of HFpEF. In addition, improved access to health services, reimbursements, and financial support may boost the congestive heart failure tratment market and improve the market accessibility of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-pipeline-insight\">emerging heart failure drugs<\/a> in the coming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1685940016841\"><strong class=\"schema-faq-question\"><strong>1. What is heart failure?<\/strong><\/strong> <p class=\"schema-faq-answer\">Heart failure, also referred to as congestive heart failure (CHF), is a condition in which the heart muscle fails to pump blood as efficiently as it should. This causes an accumulation of blood and fluid in the lungs, resulting in shortness of breath.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1685940028477\"><strong class=\"schema-faq-question\"><strong>2. What are the heart failure symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">At first, the heart failure signs and symptoms are subtle, and they are frequently misdiagnosed as typical signs of ageing. The most common symptoms of heart failure are caused by extra fluid or congestion, which leads to vessel blockage. The beginning of the congestion in the lungs is carried forward to other parts of the body. The cardiac output decreases as the disease progresses.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1685940046195\"><strong class=\"schema-faq-question\"><strong>3. What causes heart failure?<\/strong><\/strong> <p class=\"schema-faq-answer\">The most common causes of congestive heart failure include lowering the left ventricular myocardial utility and the dysfunction of the pericardium, myocardium, endocardium, heart valves or large vessels alone or in combination. Other pathogenic mechanisms that can lead to heart failure include excessive neurohumoral stimulation, irregular myocyte calcium cycling, augmented hemodynamic overload, ischemic dysfunction, ventricular remodelling, extreme or inadequate extracellular matrix production, enhanced apoptosis, and genetic mutations.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1685940058808\"><strong class=\"schema-faq-question\"><strong>4. How is heart failure diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Heart failure diagnostic tests include a chest X-ray, transthoracic echocardiography (TTE), Computerised tomography (CT) scans, and magnetic resonance imaging (MRI), Echocardiogram, Stress test, Coronary angiogram, Myocardial biopsy, Ejection fraction, and others.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/congestive-heart-failure-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-1024x256.png\" alt=\"Congestive Heart Failure Market Outlook \" class=\"wp-image-23330\" width=\"768\" height=\"192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05101919\/Congestive-Heart-Failure-Market-Outlook.png 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Heart failure is a global pandemic that affects at least 26 million people globally and is becoming more common. Heart failure health expenditures are substantial and will rise considerably as the population ages. Despite significant advancements in medicines and prevention, mortality and morbidity remain high, and quality of life remains low. The reported prevalence, incidence, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":23333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":6,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[183,20756,20486,20485,20755,635,20754,809,3677],"industry":[17225],"therapeutic_areas":[17242],"class_list":["post-23320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-congestive-heart-failure","tag-congestive-heart-failure-market","tag-congestive-heart-failure-treatment","tag-congestive-heart-failure-treatment-devices","tag-farxiga","tag-heart-failure","tag-inpefa","tag-jardiance","tag-lexicon-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LEXICON\u2019s INPEFA for Heart Failure Treatment | Key Analysis<\/title>\n<meta name=\"description\" content=\"Lexicon earned major victory as FDA accepted the company\u2019s application to market Inpefa for heart failure treatment. Dynamics of heart failure\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LEXICON\u2019s INPEFA for Heart Failure Treatment | Key Analysis\" \/>\n<meta property=\"og:description\" content=\"Lexicon earned major victory as FDA accepted the company\u2019s application to market Inpefa for heart failure treatment. Dynamics of heart failure\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-05T14:44:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-05T14:44:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05102106\/lexicon-inpefa-for-heart-failure-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LEXICON\u2019s INPEFA for Heart Failure Treatment | Key Analysis","description":"Lexicon earned major victory as FDA accepted the company\u2019s application to market Inpefa for heart failure treatment. Dynamics of heart failure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment","og_locale":"en_US","og_type":"article","og_title":"LEXICON\u2019s INPEFA for Heart Failure Treatment | Key Analysis","og_description":"Lexicon earned major victory as FDA accepted the company\u2019s application to market Inpefa for heart failure treatment. Dynamics of heart failure","og_url":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-06-05T14:44:07+00:00","article_modified_time":"2023-06-05T14:44:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05102106\/lexicon-inpefa-for-heart-failure-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment","url":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment","name":"LEXICON\u2019s INPEFA for Heart Failure Treatment | Key Analysis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05102106\/lexicon-inpefa-for-heart-failure-treatment.png","datePublished":"2023-06-05T14:44:07+00:00","dateModified":"2023-06-05T14:44:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Lexicon earned major victory as FDA accepted the company\u2019s application to market Inpefa for heart failure treatment. Dynamics of heart failure","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940016841"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940028477"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940046195"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940058808"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05102106\/lexicon-inpefa-for-heart-failure-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05102106\/lexicon-inpefa-for-heart-failure-treatment.png","width":1200,"height":800,"caption":"lexicon-inpefa-for-heart-failure-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940016841","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940016841","name":"1. What is heart failure?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Heart failure, also referred to as congestive heart failure (CHF), is a condition in which the heart muscle fails to pump blood as efficiently as it should. This causes an accumulation of blood and fluid in the lungs, resulting in shortness of breath.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940028477","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940028477","name":"2. What are the heart failure symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"At first, the heart failure signs and symptoms are subtle, and they are frequently misdiagnosed as typical signs of ageing. The most common symptoms of heart failure are caused by extra fluid or congestion, which leads to vessel blockage. The beginning of the congestion in the lungs is carried forward to other parts of the body. The cardiac output decreases as the disease progresses.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940046195","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940046195","name":"3. What causes heart failure?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The most common causes of congestive heart failure include lowering the left ventricular myocardial utility and the dysfunction of the pericardium, myocardium, endocardium, heart valves or large vessels alone or in combination. Other pathogenic mechanisms that can lead to heart failure include excessive neurohumoral stimulation, irregular myocyte calcium cycling, augmented hemodynamic overload, ischemic dysfunction, ventricular remodelling, extreme or inadequate extracellular matrix production, enhanced apoptosis, and genetic mutations.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940058808","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/lexicon-inpefa-for-heart-failure-treatment#faq-question-1685940058808","name":"4. How is heart failure diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Heart failure diagnostic tests include a chest X-ray, transthoracic echocardiography (TTE), Computerised tomography (CT) scans, and magnetic resonance imaging (MRI), Echocardiogram, Stress test, Coronary angiogram, Myocardial biopsy, Ejection fraction, and others.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/05102106\/lexicon-inpefa-for-heart-failure-treatment-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">congestive heart failure<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">congestive heart failure market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Congestive Heart Failure Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Congestive Heart Failure Treatment Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Farxiga<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Heart failure<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">INPEFA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Jardiance<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lexicon Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">congestive heart failure<\/span>","<span class=\"advgb-post-tax-term\">congestive heart failure market<\/span>","<span class=\"advgb-post-tax-term\">Congestive Heart Failure Treatment<\/span>","<span class=\"advgb-post-tax-term\">Congestive Heart Failure Treatment Devices<\/span>","<span class=\"advgb-post-tax-term\">Farxiga<\/span>","<span class=\"advgb-post-tax-term\">Heart failure<\/span>","<span class=\"advgb-post-tax-term\">INPEFA<\/span>","<span class=\"advgb-post-tax-term\">Jardiance<\/span>","<span class=\"advgb-post-tax-term\">Lexicon Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 5, 2023","modified":"Updated on Jun 5, 2023"},"absolute_dates_time":{"created":"Posted on Jun 5, 2023 8:14 pm","modified":"Updated on Jun 5, 2023 8:14 pm"},"featured_img_caption":"lexicon-inpefa-for-heart-failure-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=23320"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23320\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/23333"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=23320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=23320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=23320"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=23320"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=23320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}